This session is presented by VoLo Foundation, which has generously provided funding to support more than 200 scholarship recipients at this year's Eudēmonia. 

Medications like Ozempic and Mounjaro have become household names over the last several years, and are likely to become the best-selling drugs in the history of pharmaceuticals. Sales of these glucagon-like peptide-1 agonists, also known as “GLP-1s” have increased by more than 400% between January 2021 and December 2023, despite an annual per-patient cost of at least $12,000 — and a staggering theoretical annual cost of $2.8T were every overweight or obese American to accept treatment. In this dialogue, experts across medicine, fitness and brain health – each with a strong point of view, and evidence to back it up – will come together to drive a boldly productive debate about this “wonder drug,” and will bring to light brand new (and surprising) research about unexpected benefits that may make you reconsider what you thought you knew. Join us with an open mind.

This session will begin with a special 15-minute presentation by Voloridge Health CEO and Co-Founder, David S. Vogel, exploring how data scientists are able to reveal predictive biomarkers for chronic diseases. In addition to being CEO of Voloridge Health and leading one of the world's pre-eminent quantitative hedge fund managers, David is a pioneer in using statistical analysis to find solutions to some of humanity's greatest challenges. VoLo Foundation, Mr. Vogel’s personal foundation, has recently completed a statistical analysis of an enormous dataset of health data collected in the UK over the last 40 years, and the results indicate that the medical community may be focused on the wrong biomarkers when evaluating health and predicting all-cause mortality. VoLo Foundation has generously provided funding to support more than 200 scholarship recipients at this year's Eudēmonia.